SALT LAKE CITY (November 14,
2019) Predictive Technology Group, Inc. (OTCQX: PRED) (“Predictive” or “The
Company”), a leader in the development of genetic and molecular diagnostics and
companion therapeutics, today announced financial results for the fiscal first
quarter ended September 30, 2019 and provided a corporate update.
Management Commentary
“During our first fiscal quarter,
we were able to sustain the momentum that carried us through fiscal 2019,” said
Bradley C. Robinson, chief executive officer of Predictive Technology Group. “Total
revenues for the quarter increased 2.5% year-over-year to $8.3 million, despite
the difficult comparison driven by strong sales of human cell and tissue
products (HCT/Ps) in the year-ago period.
“Since our last quarterly update,
we successfully launched three new DNA-based test panels, including the full market
launch of ARTguide™ following the successful Key Opinion Leader (KOL) beta launch, the
KOL launch of FertilityDX™ and expanded distribution of PGxPLUS+™.
ARTguide™,
which helps detect genomic concerns associated with endometriosis and other
infertility issues in women, has now been fully commercially launched and we
expect material revenues to be generated beginning in calendar 2020. FertilityDX™, which is a comprehensive
service that identifies infertility causes, optimizes infertility treatments
and reduces risk of complications, is currently in a beta KOL development
period. We are on track with the development and distribution of these fertility
diagnostic tests that address an unmet need in the complex area of fertility
and women’s health.
“In parallel, we achieved a significant
milestone in our Predictive Biotech business, having now delivered over 100,000
allografts resulting in over 60,000 patient experiences with no serious adverse
events attributable to our products, including AmnioCyte™, AmnioCyte Plus™, PolyCyte™ and
CoreCyte™. Moving forward, in our Predictive Therapeutics business, we intend
to pursue the FDA’s 351 regulatory pathway as we advance new cellular therapeutic
candidates into clinical trials. Securing FDA approval via this pathway requires
a rigorous demonstration of a product’s efficacy and safety at a time when the
agency has increased its focus on companies offering potentially unsafe human
cell and tissue-based products as therapeutic agents. We are in a unique position
with our HCT/P platform as the significant safety experience of over 100,000
allografts used in patients in the U.S. market provides the ability to
accelerate and de-risk the clinical trial pathway for FDA approved indications.
We will announce the specific indications for which we are pursuing FDA
approval.
“We are in the early stages of
unlocking significant synergies among our business subsidiaries and are working
to further advance our broad pipeline of data analytics, therapeutics and
diagnostics to benefit both patients and our stakeholders. We are fortunate to
have highly experienced members of our advisory teams, management teams and
board of directors to bring these products to market and truly improve the quality
of life of individuals.”
Fiscal First Quarter and
Recent Highlights
Predictive
Laboratories
- Announced in October the successful U.S. launch
of ARTguide™,
the Company’s first integrated, DNA-based test to evaluate the risk for
endometriosis and other genetic causes of infertility in women, and FertilityDX™,
a comprehensive genetic testing service that identifies barriers to healthy
pregnancy and birth, allowing doctors to guide personalized fertility treatments
- Presented new genetic findings in endometriosis
at the 75th American Society of Reproductive Medicine (ASRM)
Scientific Congress & Expo
- The new findings were presented by Predictive
Laboratories’ scientific team. Predictive Technology Group is a leader in the
use of data analytics for disease identification and subsequent precision
therapeutic intervention
- The presentations focused on several features of
endometriosis, including genetic mechanisms underlying the disorder, potential
disease gene interactions, and the mechanisms through which some benign
endometriosis lesions might become cancerous
- Patent applications have been filed around these
new discoveries adding to the Company’s robust endometriosis patent portfolio
- Announced that Predictive Laboratories has
collected over 2,500 DNA samples along with comprehensive medical records since
acquiring its CLIA operations in March 2019. The subsidiary is broadening its
research initiatives by acquiring new sample collections in chronic pain,
pregnancy complications, autism, and both female and male infertility to
support the development of personalized molecular diagnostics and therapies
- In August, commercially launched PGxPLUS+™,
a pharmacogenomic test panel being marketed to pain clinics for patients living
with chronic pain
- PGxPLUS+™ evaluates genetic factors that play a
major role in an individual’s response to medications
- Predictive Laboratories reached a milestone by enrolling
350 patients with chronic pain into an Investigational Review Board-approved
clinical study aimed at providing additional insight into the mechanisms of
chronic pain and responses to pain therapies
Predictive
Biotech
- Delivered over 100,000 allografts resulting in over
60,000 patient experiences with no adverse events from AmnioCyte™, AmnioCyte
Plus™, PolyCyte™ and CoreCyte™ products
Corporate
Developments
- Announced that Kenneth Ward, M.D., laboratory
director and chief executive officer of Juneau Biosciences, Rakesh Chettier
M.S., director of biostatistics and Hans Albertsen, Ph.D., chief scientific
officer of Juneau Biosciences, received the 2019 Endometriosis Special Interest
Group (EndoSIG) Prize Paper in the “Best in Clinical/Population Science”
category
- Appointed biologic industry leader Jeff Acuff to
the newly created position of chief commercial officer of Predictive Biotech to
drive the commercial strategy of its existing HCT/P business, including the development
of new product candidates, and the expansion and use of the HCT/P into new
vertical markets
- Appointed E. Robert Wassman, M.D. as co-laboratory
director of Predictive Laboratories
- Engaged CLSA Capital Markets Limited to provide
introductions to potential strategic partners and regulatory guidance to
support the launch of Predictive’s proprietary genetic-based products into
China’s rapidly growing women’s health and fertility markets
- Engaged LifeSci Partners as communications
partner to develop and implement comprehensive investor relations and public
relations programs
Fiscal First Quarter 2020
Results
Revenue from operations (net) for
the three months ended September 30, 2019 totaled $8.3 million, compared with $8.1
million for the three months ended September 30, 2018. The increase of $0.2
million was the result of an expansion of the company’s sales force and
distribution networks leading to increased sales of HCT/Ps and regenerative medicine
products.
Cost of goods sold (“COGS”)
includes expenses associated with acquisition and processing, manufacturing
(including materials and direct labor), shipping, and other direct expenses
relating to the company’s HCT/Ps and regenerative medicine products. Cost of
goods sold for the three months ended September 30, 2019 was $7.2 million
compared with $3.0 million for the three months ended September 30, 2018. The increase is primarily due to $1.8 million in scrap
expense and $1.2 million in increased inventory reserves related to HCT/P
product that did not pass quality control, or that is not expected to pass
quality control. The increase in quality control failure rates above normal
levels was primarily due to a component supplied by a specific vendor. The
remaining increase is due to increased share-based compensation cost of $0.4
million, increased personnel costs of $0.5 million, and increased facility
costs of $0.2 million.
Sales and marketing expenses for
the three months ended September 30, 2019 were $3.2 million, compared with $2.4
million for the three months ended September 30, 2018. The increased sales and
marketing expenses resulted from increasing the headcount in the company’s sales
force.
Research and development
(R&D) expenses for the three months ended September 30, 2019 were $1.8
million, compared with $0.6 million for the three months ended September 30,
2018. The increased research and development expenses resulted from increased
focus on product development and additional proprietary research and
development work relating to the company’s HCT/Ps and regenerative medicine
products. Additionally, we have invested significant amounts in laboratory
support in anticipation of the sale of diagnostic products.
General and Administrative
(G&A) expenses for the three months ended September 30, 2019 were $6.4
million compared with $2.7 million for the three months ended September 30,
2018. The changes in general and administrative expenses resulted from
increased management headcount and share based compensation expense in fiscal
2020.
Amortization and depreciation
expense for the three months ended September 30, 2019 was $2.6 million,
compared with $1.7 million for the three months ended September 30, 2018. The
reason for the increase in amortization and depreciation expense relates
primarily to the amortization of intangible assets acquired from acquisitions.
The net loss attributable to common
shareholders for the three months ended September 30, 2019 was $7.9 million, or
$0.03 per share, versus a net loss attributable to common shareholders for the
three months ended September 30, 2018 of $2.0 million, or $0.01 per share.
About Predictive Laboratories,
Inc.
Predictive Laboratories’ discoveries in molecular and genetic
diagnostics focus on unmet needs in women’s health, infertility and other
diseases. Predictive Laboratories offers earlier detection of disease through
genetic assessment to guide personalized precision medicine. Leveraging its
vast genetic database, Predictive Laboratories enables the discovery of genes
and gene mutations that identify hard-to-diagnose and detect diseases and their
prognosis.
The Company’s proprietary tests include ARTguideTM and
FertilityDXTM. ARTguideTM is a blood test that assesses a
woman’s endometriosis risk and other genetic causes of infertility in order to
optimally navigate the path towards conception. FertilityDXTM is a
comprehensive test and service, using the parental genetic assessment as the
map to guide the journey to successful pregnancy and a healthy newborn.
Predictive Laboratories’ tests are processed at the Company’s state-of-the-art
CAP-accredited, CLIA-certified laboratory, equipping physicians with the robust
diagnostic tools to provide personalized treatment for their patients. For more
information, visit www.predictivelabs.com.
About Predictive Biotech, Inc.
Predictive Biotech, Inc., a Salt Lake City-based life sciences company
formed in 2015, is a leader in human cell and tissue products for use in
cellular therapies and regenerative medicine. A growing national network of
clinics, health systems, researchers and physicians leverage Predictive’s four
main placental-derived and Wharton’s Jelly umbilical cord-derived products.
Predictive Biotech’s current products are regulated by the FDA under 21 CFR
part 1271 section 361 as minimally manipulated allografts intended for
homologous use.
About Predictive Technology Group, Inc.
Predictive Technology
Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive
gene-based analytics to develop genetic and molecular diagnostic tests, as well
as companion therapeutics, in order to support a patient from diagnosis through
treatment. The Companies’ tests and products empower clinicians to provide
their patients with the highest level of care.
Predictive’s subsidiaries include Predictive Laboratories, Predictive
Biotech and Predictive Therapeutics. For
more information, visit www.predtechgroup.com.
Forward-Looking Statements:
To the extent
any statements made in this release contain information that is not historical,
these statements are essentially forward-looking and are subject to risks and
uncertainties, including the difficulty of predicting FDA approvals, acceptance
and demand for human cell and tissue products and other pharmaceutical
products, the impact of competitive products and pricing, new product
development and launch, reliance on key strategic alliances, availability of
raw materials, availability of additional intellectual property rights,
availability of future financing sources, the regulatory environment, and other
risks the Company may identify from time to time in the future.
Contacts:
For more information, visit
www.predtechgroup.com
ELEMENT GLOBAL, INC. (ELGL) PROVIDES CORPORATE UPDATE
/in Element Global, Inc., Press Releases /by Yes InternationalLos Angeles, CA- January 2, 2020- Element Global, Inc. (ELGL:OTC) provides a corporate update regarding its operational on-goings.Throughout 2019, Management made enormous strides to move the Company forward, with the primary objective of value-added opportunities.
In June 2019, ELGL organized an Exploratory Committee (“Committee”) to evaluate the best possible outcomes of ALL business decisions as it relates to being accretive to ELGL’s operational growth. Through its business subsidiaries in mining, energy, technologies, media, sports, and finance, management remains diligent in creating several revenue streams, which in turn can create shareholder value.
Currently, Management remains committed to getting ELGL to become a fully-reporting US SEC entity. As such, the Board of Directors and officers at ELGL, under the suggestion of the “Committee,” began to look at the best possible way to become a US SEC filer. At this time, the best possible, least costly and timely outcome looks to merger ELGL and its assets into an existing fully-reporting company. If such an arrangement becomes possible, management will structure such a merger whereas ELGL becomes the surviving entity.
The ELGL team continued to evaluate the prospect of such a merger, and began in earnest with extensive due diligence with targeted US SEC fully reporting entities. Upon final due diligence on targets, Management believes that a merger deal could be obtainable to become fully-reporting with the best possible outcomes of both time and expense.
If an arrangement can consummate itself, management expects to proceed with necessary non-disclosures, term sheets, and other legal documents.
Once more information becomes available as warranted, updates to follow, accordingly.
One can obtain further information, contact, YES INTERNATIONAL, Investor relations, 757-306-6090, info@elementglobal.com, www.elementglobal.com, & www.yesinternational.com
About Element Global Inc.
Element Global, Inc. (ELGL:OTCMARKETS), a diversified holding company with global business interests centered on renewable energy, technology, media and production, distribution and AVOD/SVOD streaming on its platform in original and licensed film and TV content globally, brings together these enterprises to capitalize on both domestic and international opportunities. As new energy and smart digital technologies converge globally, which supports emission reductions through the electrification of power, transport, industry, and buildings, ELGL envisions itself capitalizing on the increases in demand in these industries, www.elementglobal.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
BRAVO MULTINATIONAL INCORPORATED (BRVO) Announces a “LETTER OF INTENT” to Acquire ELEMENT GLOBAL, INC.’s (ELGL) Subsidiary ELEMENT GLOBAL MINING
/in Bravo Multinational Incorporated, Element Global, Inc., Press Releases /by Yes InternationalVirginia Beach, VA- December 30, 2019—BRAVO MULTINATIONAL INCORPORATED (OTC:BRVO) and ELEMENT GLOBAL, INC. (OTC.ELGL) announces a “Letter of Intent,” whereas BRVO acquires ELGL’s subisidiary, ELEMENT GLOBAL MINING (EGM).
The “Letter of Intent” provided for negotiations and due diligence, with an expected outcome of an acquisition of ELEMENT GLOBAL MINING (EGM). BRVO believes this acquisition should bring significant value to the Company and its shareholders.
For further information about this release, contact Investor Relations, YES INTERNATIONAL, at 757-306-6090 and yes@yesinternational.com, www.elementglobal.com and www.bravomultinational.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
Predictive Technology Group Reports First Quarter Fiscal 2020 Financial Results and Provides Corporate Update
/in Predictive Technology Group /by Yes InternationalSALT LAKE CITY (November 14, 2019) Predictive Technology Group, Inc. (OTCQX: PRED) (“Predictive” or “The Company”), a leader in the development of genetic and molecular diagnostics and companion therapeutics, today announced financial results for the fiscal first quarter ended September 30, 2019 and provided a corporate update.
Management Commentary
“During our first fiscal quarter, we were able to sustain the momentum that carried us through fiscal 2019,” said Bradley C. Robinson, chief executive officer of Predictive Technology Group. “Total revenues for the quarter increased 2.5% year-over-year to $8.3 million, despite the difficult comparison driven by strong sales of human cell and tissue products (HCT/Ps) in the year-ago period.
“Since our last quarterly update, we successfully launched three new DNA-based test panels, including the full market launch of ARTguide™ following the successful Key Opinion Leader (KOL) beta launch, the KOL launch of FertilityDX™ and expanded distribution of PGxPLUS+™. ARTguide™, which helps detect genomic concerns associated with endometriosis and other infertility issues in women, has now been fully commercially launched and we expect material revenues to be generated beginning in calendar 2020. FertilityDX™, which is a comprehensive service that identifies infertility causes, optimizes infertility treatments and reduces risk of complications, is currently in a beta KOL development period. We are on track with the development and distribution of these fertility diagnostic tests that address an unmet need in the complex area of fertility and women’s health.
“In parallel, we achieved a significant milestone in our Predictive Biotech business, having now delivered over 100,000 allografts resulting in over 60,000 patient experiences with no serious adverse events attributable to our products, including AmnioCyte™, AmnioCyte Plus™, PolyCyte™ and CoreCyte™. Moving forward, in our Predictive Therapeutics business, we intend to pursue the FDA’s 351 regulatory pathway as we advance new cellular therapeutic candidates into clinical trials. Securing FDA approval via this pathway requires a rigorous demonstration of a product’s efficacy and safety at a time when the agency has increased its focus on companies offering potentially unsafe human cell and tissue-based products as therapeutic agents. We are in a unique position with our HCT/P platform as the significant safety experience of over 100,000 allografts used in patients in the U.S. market provides the ability to accelerate and de-risk the clinical trial pathway for FDA approved indications. We will announce the specific indications for which we are pursuing FDA approval.
“We are in the early stages of unlocking significant synergies among our business subsidiaries and are working to further advance our broad pipeline of data analytics, therapeutics and diagnostics to benefit both patients and our stakeholders. We are fortunate to have highly experienced members of our advisory teams, management teams and board of directors to bring these products to market and truly improve the quality of life of individuals.”
Fiscal First Quarter and Recent Highlights
Predictive Laboratories
Predictive Biotech
Corporate Developments
Fiscal First Quarter 2020 Results
Revenue from operations (net) for the three months ended September 30, 2019 totaled $8.3 million, compared with $8.1 million for the three months ended September 30, 2018. The increase of $0.2 million was the result of an expansion of the company’s sales force and distribution networks leading to increased sales of HCT/Ps and regenerative medicine products.
Cost of goods sold (“COGS”) includes expenses associated with acquisition and processing, manufacturing (including materials and direct labor), shipping, and other direct expenses relating to the company’s HCT/Ps and regenerative medicine products. Cost of goods sold for the three months ended September 30, 2019 was $7.2 million compared with $3.0 million for the three months ended September 30, 2018. The increase is primarily due to $1.8 million in scrap expense and $1.2 million in increased inventory reserves related to HCT/P product that did not pass quality control, or that is not expected to pass quality control. The increase in quality control failure rates above normal levels was primarily due to a component supplied by a specific vendor. The remaining increase is due to increased share-based compensation cost of $0.4 million, increased personnel costs of $0.5 million, and increased facility costs of $0.2 million.
Sales and marketing expenses for the three months ended September 30, 2019 were $3.2 million, compared with $2.4 million for the three months ended September 30, 2018. The increased sales and marketing expenses resulted from increasing the headcount in the company’s sales force.
Research and development (R&D) expenses for the three months ended September 30, 2019 were $1.8 million, compared with $0.6 million for the three months ended September 30, 2018. The increased research and development expenses resulted from increased focus on product development and additional proprietary research and development work relating to the company’s HCT/Ps and regenerative medicine products. Additionally, we have invested significant amounts in laboratory support in anticipation of the sale of diagnostic products.
General and Administrative (G&A) expenses for the three months ended September 30, 2019 were $6.4 million compared with $2.7 million for the three months ended September 30, 2018. The changes in general and administrative expenses resulted from increased management headcount and share based compensation expense in fiscal 2020.
Amortization and depreciation expense for the three months ended September 30, 2019 was $2.6 million, compared with $1.7 million for the three months ended September 30, 2018. The reason for the increase in amortization and depreciation expense relates primarily to the amortization of intangible assets acquired from acquisitions.
The net loss attributable to common shareholders for the three months ended September 30, 2019 was $7.9 million, or $0.03 per share, versus a net loss attributable to common shareholders for the three months ended September 30, 2018 of $2.0 million, or $0.01 per share.
About Predictive Laboratories, Inc.
Predictive Laboratories’ discoveries in molecular and genetic diagnostics focus on unmet needs in women’s health, infertility and other diseases. Predictive Laboratories offers earlier detection of disease through genetic assessment to guide personalized precision medicine. Leveraging its vast genetic database, Predictive Laboratories enables the discovery of genes and gene mutations that identify hard-to-diagnose and detect diseases and their prognosis.
The Company’s proprietary tests include ARTguideTM and FertilityDXTM. ARTguideTM is a blood test that assesses a woman’s endometriosis risk and other genetic causes of infertility in order to optimally navigate the path towards conception. FertilityDXTM is a comprehensive test and service, using the parental genetic assessment as the map to guide the journey to successful pregnancy and a healthy newborn. Predictive Laboratories’ tests are processed at the Company’s state-of-the-art CAP-accredited, CLIA-certified laboratory, equipping physicians with the robust diagnostic tools to provide personalized treatment for their patients. For more information, visit www.predictivelabs.com.
About Predictive Biotech, Inc.
Predictive Biotech, Inc., a Salt Lake City-based life sciences company formed in 2015, is a leader in human cell and tissue products for use in cellular therapies and regenerative medicine. A growing national network of clinics, health systems, researchers and physicians leverage Predictive’s four main placental-derived and Wharton’s Jelly umbilical cord-derived products. Predictive Biotech’s current products are regulated by the FDA under 21 CFR part 1271 section 361 as minimally manipulated allografts intended for homologous use.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics. For more information, visit www.predtechgroup.com.
Forward-Looking Statements:
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contacts: For more information, visit www.predtechgroup.com
Predictive Technology Group Provides Stock Trading Platform Update
/in Predictive Technology Group, Press Releases /by Yes InternationalSALT LAKE CITY, Nov. 11, 2019 — Predictive Technology Group, Inc. (OTC Pink: PRED), a leader in the development of genetic and molecular diagnostics and companion therapeutics, today announced that effective on November 6, 2019, the company’s shares commenced trading on the Pink® market from the OTCQX® market previously.
Bradley C. Robinson, Chief Executive Officer of Predictive Technology Group, said, “We are aware of the change in trading platform for our shares from the OTCQX® market to the Pink® market. While we are disappointed in and strongly disagree with the OTC’s decision, we remain committed to uplisting to a national securities exchange, and are working through the process of satisfying that exchange’s rigorous listing requirements as expeditiously as possible. In the meantime, the fundamentals of our company remain strong, and we are working tirelessly to become a leader in the development of novel gene-based diagnostics and companion and cellular therapeutics to address serious and debilitating diseases.”
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics. For more information, visit www.predtechgroup.com.
Forward-Looking Statements:
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contacts: For more information, visit www.predtechgroup.com
Predictive Technologies Group Engages LifeSci Partners as Communications Partner
/in Predictive Technology Group, Press Releases /by Yes InternationalLifeSci to develop and execute comprehensive public relations and investor relations programs
SALT LAKE CITY, Oct. 31, 2019 (GLOBE NEWSWIRE) — Predictive Technology Group, Inc. (OTCQX: PRED) (“Predictive” or “The Company”), a leader in the development of genetic and molecular diagnostics and companion therapeutics, announced that it has engaged with LifeSci Partners (“LifeSci”) to increase awareness of the company’s brand and clinical programs.
“We are excited to work with LifeSci to inform the public and the investment community about our innovative data analytics that help physicians identify and combat diseases using our unique treatments and therapeutics,” said Bradley C. Robinson, president and chief executive officer of Predictive. “LifeSci’s expertise in investor relations and public relations, as well as their decades of experience in capital markets, media relations and scientific research have made them the perfect communications partner for our company as we work to grow our business and reach new audiences.”
LifeSci is a leading provider of strategic consulting services in the areas of investor relations, public relations, corporate communications, executive search and capital markets advisory. LifeSci Advisors, LLC and LifeSci Public Relations will provide Predictive with integrated communications services through strategic messaging, investor and media outreach, social and digital media efforts.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics. For more information, visit www.predtechgroup.com.
About LifeSci Advisors
LifeSci Advisors is a division of LifeSci Partners (www.lifescipartners.com), a leading provider of consulting services for life sciences clients in the areas of investor relations, public relations, corporate communications, executive search, strategic partnering and capital markets advisory. LifeSci combines deep domain expertise and decades of experience in capital markets and communications with a global network to deliver unparalleled services to clients. LifeSci Advisors is the largest investor relations consultancy in the life sciences industry, founded to provide companies with a multi-faceted approach to investor communications and outreach. LifeSci Advisor’s team of financial services and investor relations specialists synergistically pair with LifeSci Public Relations’ team of MDs and PhDs, positioning the firm to best communicate its clients’ scientific, R&D, regulatory and commercial strategies to diverse audiences. LifeSci Partners’ addition of executive search, strategic partnering and capital markets advisory capabilities provides fully integrated business solutions for life sciences clients across all stages of development.
Forward-Looking Statements:
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contacts: For more information, visit www.predtechgroup.com
Predictive Technologies Group PRED Upgrades to OTCQX® Best Market
/in Predictive Technology Group, Press Releases /by Yes InternationalSALT LAKE CITY, Oct. 24, 2019 (GLOBE NEWSWIRE) — Predictive Technology Group, Inc. (OTCQX: PRED), a leader in the development of genetic and molecular diagnostics and companion therapeutics, today announced that the company has been upgraded to the OTCQX® Best Market from the Pink® market. Effective today, the company’s shares will trade under the ticker “PRED.” U.S. investors can find current financial disclosures and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
“We are pleased to upgrade to the OTCQX® Best Market and believe this is a testament to the Predictive team who work to continuously improve our financial standards and corporate governance practices,” said Bradley C. Robinson, President and Chief Executive Officer of Predictive Technologies Group. “We welcome the broader investor reach and heightened visibility among the investment community that the OTCQX® Best Market confers on its traded companies.”
“We are pleased to be accepted to trade on the OTCQX Best Market. Our previously announced listing application for the NASDAQ Market exchange is currently in the review process,” Mr. Robinson concluded.
Burns Figa & Will PC acted as the company’s OTCQX sponsor.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics. For more information, visit www.predtechgroup.com.
Forward-Looking Statements:
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contacts: For more information, visit www.predtechgroup.com
Predictive Laboratories Team Led by Laboratory Director Kenneth Ward, M.D. Receives 2019 Endometriosis Special Interest Group Prize Paper Award
/in Predictive Technology Group, Press Releases /by Yes InternationalResearch presented by Dr. Hans Albertsen of Juneau Biosciences advancing knowledge of the genetic factors contributing to endometriosis receives award at the 2019 American Society of Reproductive Medicine (ASRM) Scientific Congress & Expo
SALT LAKE CITY (October 17, 2019) — Predictive Laboratories, a wholly owned molecular and genetic diagnostics company of Predictive Technology Group (OTC Pink: PRED) focused on hard-to-detect diseases, women’s health and infertility, announces Kenneth Ward, M.D., laboratory director of Predictive Laboratories and chief executive officer of Juneau Biosciences; Rakesh Chettier M.S., director of biostatistics of Predictive Laboratories; and Hans Albertsen, Ph.D., chief scientific officer of Juneau Biosciences, have received the 2019 Endometriosis Special Interest Group (EndoSIG) Prize Paper in the “Best in Clinical/Population Science” category.
Dr. Albertsen’s presentation entitled “Cytoskeletal and extra cellular matrix genes are key contributors in the pathogenesis of endometriosis” was delivered at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress & Expo in Philadelphia on October 16. EndoSIG is a member group of ASRM aimed at fostering increased interest in the biology, pathophysiology and clinical management of endometriosis.
“We are honored to receive this prestigious award from the ASRM Research Committee,” said Dr. Albertsen. “As endometriosis is generally characterized as a hormonal and inflammatory disease, current therapies often come with significant debilitating side effects. The scientific breaktroughs reported in these award-winning discoveries provide Predictive with insights into new non-hormonal therapies.”
The team’s research is based on the genetic markers of endometriosis discovered by Juneau and Predictive scientists in recent years, and uncovers molecular pathways involved in the pathogenesis of endometriois-induced lesions in women at risk for the disease. Juneau’s gene discovery work in endometriosis was also awarded the EndoSIG Prize Paper in 2015 and 2018.
Dr. Ward, a board-certified physician in obstetrics and gynecology, perinatology, clinical genetics and molecular genetics, presented two scienfic papers at the Annual ASRM meeting: a poster entitled, “Endometriosis risk allele in WNT4 may interact with rare mutations in HDAC2 gene” and an oral abstract entitled, “Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk.”
“We are tremendously proud of Drs. Ward and Albertsen and the teams at Predictive Laboratories and Juneau Biosciences for their research, collaborations and continued devotion to endometriosis and other gene discoveries that advance our understanding of fertility and women’s health, and lead to healthy newborns,” said Bradley Robinson, chief executive officer of Predictive Technology Group. “ASRM brings leaders in reproductive care together from across the world to share findings, inspire new methodology and encourage collaboration to promote further development in reproductive medicine.”
In June 2019, Predictive Laboratories and Thermo Fisher Scientific announced a global research collaboration to study underlying genetic factors contributing to female infertility. The two companies conducted meetings at ASRM in Philadelphia. This partnership pairs Predictive’s innovative research and development capabilities with Thermo Fisher’s market-leading next generation sequencing technology and analytical capabilities to accelerate the understanding of the genetics affecting infertility for future development of diagnostic solutions.
About Predictive Laboratories
Predictive Laboratories’ discoveries in molecular and genetic diagnostics focus on unmet needs in women’s health, infertility and other diseases. Predictive Laboratories offers earlier detection of disease through genetic assessment to guide personalized precision medicine. Leveraging its vast genetic database, Predictive Laboratories enables the discovery of genes and gene mutations that identify hard-to-diagnose and detect diseases and their prognosis.
The Company’s proprietary tests include ARTguideTM and FertilityDXTM. ARTguide is a blood test that assesses a woman’s endometriosis risk and other genetic causes of infertility in order to optimally navigate the path towards conception. FertilityDX is a comprehensive test and service, using the parental genetic assessment as the map to guide the journey to successful pregnancy and a healthy newborn. Predictive Laboratories’ tests are processed at the Company’s state-of-the-art CAP-accredited, CLIA-certified laboratory, equipping physicians with the robust diagnostic tools to provide personalized treatment for their patients. For more information, visit www.predictivelabs.com.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics. For more information, visit www.predtechgroup.com.
Forward-Looking Statements:
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
ELEMENT GLOBAL, INC . (ELGL) LAUNCHES NEW CORPORATE WEBSITE
/in Element Global, Inc., Press Releases /by Yes InternationalLos Angeles, CA- October 15, 2019- ELEMENT GLOBAL, INC. (ELGL:OTCMARKETS) announces its new corporate website, www.elementglobal.com.
The site brings the vision of the Company’s objectives through its many holdings, enabling visitors the opportunity to learn more. As ELGL grows, expect its website to be updated timely to provide comprehensive information.
Merle Ferguson, Chairman at ELGL, states, “Created with the user experience in mind, the site includes many features to help visitors quickly understand the Company’s vertical businesses in mining, energy, sports, technology, media and finance.”
Excited about the new ELGL website, management believes visitors can find information with ease, and enables both customers and shareholders corporate information and content.
One can obtain further information, contact, YES INTERNATIONAL, Investor relations, 757-306-6090, info@elementglobal.com, and www.elementglobal.com. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition
Predictive Technology Group Engages CLSA Capital Markets Limited, a CITIC Securities Company, to Support Product Launches into China’s Rapidly Growing Women’s Health and Fertility Market
/in Predictive Technology Group, Press Releases /by Yes InternationalSALT LAKE CITY –October 15, 2019– Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the development of genetic and molecular diagnostics and companion therapeutics, announces that it has engaged CLSA Capital Markets Limited, a CITIC Securities Company, to provide introductions to potential strategic partners and regulatory guidance to support the launch of its proprietary genetic-based products into China’s (PRC) rapidly growing markets for women’s health and fertility. Terms of the transaction were not disclosed.
“Given our genetic library, research and understanding of genetics, endometriosis and other factors that may affect a woman’s fertility, we are excited to bring our noninvasive testing technology to this large, emerging market that already surpasses the U.S. in terms of the number of affected women,” said Bradley Robinson, Chief Executive Officer of Predictive Technology Group. “Our tests help both the doctor and patient understand and navigate the barriers to fertility, changing the path to a healthy baby. We are especially pleased to collaborate in this endeavor with CLSA, a leading capital markets and investment group in Asia.”
Predictive expects to introduce ARTguide™ among other fertility diagnostics to the Chinese market. On October 14, 2019, Predictive launched the full U.S. market availability of ARTguide, its test to evaluate the risk for endometriosis and other genetic causes of infertility in women, at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress and Expo in Philadelphia.
In 2016 the National Health and Family Planning Commission of the PRC reported that 40 million Chinese couples were experiencing fertility issues. Similarly, the American Society for Reproductive Medicine (ASRM) reported in 2017 that an estimated 25% of Chinese women of childbearing age struggled with infertility issues. In 2018 the European Society of Human Reproduction and Embryology estimated that approximately 800,000 assisted reproductive technology (ART) cycles, such as in vitro fertilization (IVF), were being performed in China annually. Chinese women are driving the fertility markets both in China and medical tourism industries overseas. The global IVF market is expected to grow at an annual rate of 10.2% and to reach $36.2 billion by 2026. The U.S. Center for Disease Control reported that of the patients who sought fertility care in 2017, 284,385 ART cycles were performed resulting in 78,052 live born infants with ART accounting for 1.7% of all infants born in the U.S. annually.
Predictive Laboratories ARTguide Test
ARTguide is the first integrated, DNA-based test that evaluates the risk for endometriosis and other genetic causes of infertility in women. It provides a greater understanding of over a dozen genetic conditions affecting a woman’s fertility by identifying previously invisible barriers to conception, consequently improving ART success rates. ARTguide is appropriate for all women considering use of ART to overcome difficulty conceiving or carrying a pregnancy.
ARTguide was introduced to a limited number of U.S. clinics in 2018. Predictive Laboratories is a wholly owned molecular and genetic diagnostics company of Predictive Technology Group focused on hard-to-detect diseases, women’s health and infertility. Predictive Laboratories recently completed a laboratory expansion to add capacity that allows ARTguide to be available more broadly in the U.S.
Endometriosis
Endometriosis is an estrogen-responsive, chronic condition that arises from extra-uterine growth of the stromal or glandular tissue that line the uterus. Often called the “invisible disease,” endometriosis affects an estimated 1 in 10 women in the U.S. during their reproductive years with many cases go undiagnosed. It is common for a woman to experience symptoms—such as chronic pelvic pain, heavy or painful periods—for a decade or more before a diagnosis is made (13 years, on average, in China). The current standard for diagnosis is laparoscopic surgery, to biopsy lesions found within the fallopian tubes or uterus. Even with this surgery, intraoperative diagnosis by conventional laparoscopic visualization is frequently difficult and inaccurate.
Severe endometriosis with extensive scarring and organ damage is one of the most common causes of female infertility. However, endometriosis can still affect fertility when no symptoms are present. 30% to 50% of women with endometriosis may experience infertility, and 25% to 50% of women who experience infertility have endometriosis.
Studies have linked the risk of endometriosis to ethnicity, with several reporting Asian women’s risk being nine times greater than that of Caucasian women. A recent systematic review analyzing the outcomes of more than 1.9 million Chinese women found endometriosis to be associated with the worsening of obstetric and pregnancy-related outcomes, including miscarriage, pre-term labor, placenta previa, small for gestational age, and caesarean delivery compared to healthy controls.
Predictive Laboratories, Inc.
Predictive Laboratories’ discoveries in molecular and genetic diagnostics focus on unmet needs in women’s health, infertility and other diseases. Predictive offers earlier detection of disease through genetic assessment to guide personalized precision medicine. Leveraging its vast genetic database, Predictive enables the discovery of genes and gene mutations that identify hard-to-diagnose and detect diseases and their prognosis. For more information, visit www.predictivelabs.com.
Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics. For more information, visit www.predtechgroup.com.
CLSA Capital Markets Limited
CLSA is Asia’s leading capital markets and investment group, providing global investors with insights, liquidity, and capital to drive their investment strategies. Award-winning research, an extensive Asia footprint, direct links to China, and highly experienced finance professionals differentiate our innovative products and services in asset management, corporate finance, capital, and debt markets, securities, and wealth management. As the international platform of CITIC Securities (SSE: 600030, SEHK: 6030), China’s largest investment bank, CLSA is uniquely positioned to facilitate cross-border capital flows and connect China with the world and the world to China. Founded in 1986 and headquartered in Hong Kong, CLSA’s global network spans 21 locations across Asia, Australia, Europe, and the United States. For more information, visit www.clsa.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
For more information, visit www.predtechgroup.com
Predictive Laboratories Launches FertilityDX™
/in Predictive Technology Group, Press Releases /by Yes InternationalGenetic testing service now available to identify causes of infertility and guide personalized fertility treatments
SALT LAKE CITY, Oct. 14, 2019– Predictive Laboratories, a wholly owned molecular and genetic diagnostics company of Predictive Technology Group (OTC Pink: PRED) focused on hard-to-detect diseases, women’s health and infertility, announces the launch of FertilityDX™, a comprehensive genetic testing service that identifies barriers to healthy pregnancy and birth, allowing doctors to tailor fertility treatments. The test launch will be formally announced at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress and Expo, Oct. 12-16 in Philadelphia.
“For the one in eight couples who struggle with infertility, trying to have a child can be financially, physically and emotionally exhausting—largely because the couple doesn’t know why they are having difficulty conceiving,” said Kenneth Ward, M.D., Laboratory Director of Predictive Laboratories. Dr. Ward is a board-certified physician in obstetrics and gynecology, perinatology, clinical genetics and molecular genetics. “Our desire is to arm couples considering assisted reproductive technologies (ART) with an understanding of the genetic and medical obstacles that may be affecting their fertility and provide doctors with genetically relevant information to help their patients have a healthy baby.”
FertilityDX provides information by evaluating three key areas: contributors to (or causes of) infertility, risks of pregnancy complications, and risks for serious genetic conditions in offspring.
FertilityDX supports both physician and patient throughout the entirety of the treatment process. Patients are provided with pretest counseling and clear and relevant test results. Physicians get an easy-to-understand final report and access to a variety of genetics consultants. The test will be launched in select fertility clinics across the United States, offering couples access to the most comprehensive genetic service to date.
About Predictive Laboratories
Predictive Laboratories’ discoveries in molecular and genetic diagnostics focus on unmet needs in women’s health, infertility and other diseases. Predictive Laboratories offers earlier detection of disease through genetic assessment to guide personalized precision medicine. Leveraging its vast genetic database, Predictive Laboratories enables the discovery of genes and gene mutations that identify hard-to-diagnose and detect diseases and their prognosis.
The Company’s proprietary tests include ARTguideTM and FertilityDXTM. ARTguide is a blood test that assesses a woman’s endometriosis risk and other genetic causes of infertility in order to optimally navigate the path towards conception. FertilityDX is a comprehensive test and service, using the parental genetic assessment as the map to guide the journey to successful pregnancy and a healthy newborn. Predictive Laboratories’ tests are processed at the Company’s state-of-the-art CAP-accredited, CLIA-certified laboratory, equipping physicians with the robust diagnostic tools to provide personalized treatment for their patients. For more information, visit www.predictivelabs.com.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, to support a patient from diagnosis through treatment. The companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics. For more information, visit www.predtechgroup.com.
Forward-Looking Statements:
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.